Core Viewpoint - Bavarian Nordic has entered into an exclusive agreement with Eurofarma to sell and distribute its chikungunya vaccine, CHIKV VLP, in Brazil, with potential expansion to the rest of Latin America [1][8] Group 1: Agreement Details - The agreement is based on transfer pricing and royalties, with no upfront or milestone payments involved [2] - Eurofarma will be responsible for seeking and maintaining regulatory approval for the vaccine in the exclusive territories, as well as covering sales and distribution costs [2] - Bavarian Nordic will continue to manufacture the vaccine, which will be provided to Eurofarma under a transfer pricing agreement [2] Group 2: Regulatory and Market Launch - The regulatory submission is expected to occur in the first half of 2026, depending on discussions with the Brazilian health authority, Anvisa, potentially supporting the vaccine's launch in Brazil in the second half of 2027 [3] - The partnership aims to improve access to chikungunya vaccines in Brazil, which accounts for half of all reported cases and related deaths globally [4][7] Group 3: Vaccine Information - CHIKV VLP is a single-dose, recombinant vaccine designed to provide active preventive immunization against chikungunya virus disease for individuals aged 12 and older [5] - The vaccine is non-infectious as it contains no viral genetic material, allowing a broad group of individuals to benefit from vaccination [6] - It was approved by the U.S. FDA and the European Commission in February 2025, and in the UK in May 2025 under the name VIMKUNYA [6] Group 4: Company Background - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines [8] - Eurofarma, founded in 1972, is a leading pharmaceutical company in Brazil, operating in 24 countries and producing 600 million units in 2024, with a net revenue of over USD 1.78 billion [10]